other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}

Adviser Profile

As of Date 03/26/2024
Adviser Type - Large advisory firm
Number of Employees 24 -25.00%
of those in investment advisory functions 15 -16.67%
Registration SEC, Approved, 06/26/2014
Other registrations (1)
AUM* 4,490,893,812 -13.01%
of that, discretionary 4,490,893,812 -13.01%
Private Fund GAV* 4,476,819,803 -12.69%
Avg Account Size 374,241,151 8.74%
SMA’s No
Private Funds 4 1
Contact Info 212 xxxxxxx
Websites

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
8B 7B 6B 4B 3B 2B 1B
2015 2016 2017 2018 2019 2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypeHedge Fund Count3 GAV$4,469,413,431
Fund TypeVenture Capital Fund Count1 GAV$7,406,372

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser 1SHARPE CAPITAL LLC Hedge Fund2.2b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund24.7m Other Fund- Total Private Fund GAV2.3b AUM2.3b #Funds5
Adviser COLCHIS CAPITAL MANAGEMENT, L.P. Hedge Fund921.2m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund11.7m Other Fund- Total Private Fund GAV944.6m AUM1.1b #Funds5
Adviser MESON CAPITAL PARTNERS LLC Hedge Fund114.5m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund9.3m Other Fund- Total Private Fund GAV133.1m AUM- #Funds5
Adviser ARS INVESTMENT PARTNERS, LLC Hedge Fund13.8m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund7.1m Other Fund- Total Private Fund GAV27.9m AUM1.6b #Funds4
Adviser AROSA CAPITAL MANAGEMENT LP Hedge Fund718.6m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund16.0m Other Fund- Total Private Fund GAV750.5m AUM727.2m #Funds4
Adviser AWM INVESTMENT COMPANY INC Hedge Fund875.3m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund25.0m Other Fund- Total Private Fund GAV925.4m AUM900.4m #Funds8
Adviser CANNELL CAPITAL LLC Hedge Fund565.4m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund1.4m Other Fund- Total Private Fund GAV568.1m AUM851.8m #Funds4
Adviser TCM GLOBAL ASSET MANAGEMENT LTD Hedge Fund- Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV- AUM- #Funds-
Adviser ALKEON CAPITAL MANAGEMENT, LLC Hedge Fund24.3b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund85.1m Other Fund68.1m Total Private Fund GAV24.5b AUM17.3b #Funds23
Adviser MIO PARTNERS, INC. Hedge Fund20.1b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund30.7m Other Fund- Total Private Fund GAV20.2b AUM47.8b #Funds14

Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
Stck Ticker78462F103 Stock NameSPDR S&P 500 ETF TR (PUT) $ Position$315,568,000 % Position10.00% $ Change16.00% # Change10.00%
Stck TickerG1110E107 Stock NameBIOHAVEN LTD $ Position$259,804,973 % Position8.00% $ Change44.00% # Change0.00%
Stck Ticker50127T109 Stock NameKURA ONCOLOGY INC $ Position$149,535,360 % Position5.00% $ Change3.00% # Change8.00%
Stck Ticker457669307 Stock NameINSMED INC $ Position$119,406,757 % Position4.00% $ Change-29.00% # Change-35.00%
Stck Ticker46116X101 Stock NameINTRA-CELLULAR THERAPIES INC $ Position$105,293,532 % Position3.00% $ Change-2.00% # Change-8.00%
Stck Ticker30303M102 Stock NameMETA PLATFORMS INC $ Position$96,449,271 % Position3.00% $ Change14.00% # Change1.00%
Stck Ticker037833100 Stock NameAPPLE INC $ Position$78,322,251 % Position3.00% $ Change2.00% # Change-7.00%
Stck Ticker03969K108 Stock NameARCUTIS BIOTHERAPEUTICS INC $ Position$99,710,052 % Position3.00% $ Change7.00% # Change7.00%
Stck Ticker08205P209 Stock NameBENITEC BIOPHARMA INC $ Position$81,138,997 % Position3.00% $ Change586.00% # Change422.00%
Stck Ticker91324P102 Stock NameUNITEDHEALTH GROUP INC $ Position$85,857,335 % Position3.00% $ Change4.00% # Change-9.00%

Brochure Summary

Overview

Suvretta Capital Management, LLC (the “Adviser” or “Suvretta”), a Delaware limited liability company, is a New York-based investment management firm founded by Aaron Cowen (the “Managing Member”) in 2011. The owner of the Adviser is Suvretta Capital, LP, a Delaware limited partnership, and its general partner is Suvretta Capital GP, LLC, a Delaware limited liability company. As of December 31, 2023, Suvretta’s regulatory assets under management were approximately $4,490,900,000. As of the date of this filing, Suvretta does not manage any assets on a non-discretionary basis. Suvretta provides discretionary investment management services to private pooled investment vehicles (each a “Fund” and collectively the “Funds”) intended for sophisticated investors and institutional investors (“Fund Investors”). The Funds Suvretta manages include:
• Suvretta Partners, LP (the “Onshore Fund”) and Suvretta Offshore Fund, Ltd. (the “Offshore Fund”), which invest substantially all of their assets in Suvretta Master Fund, Ltd. (the “Suvretta Fund,” and collectively with the Onshore Fund and the Offshore Fund, the “Long-Short Funds”);
• Averill Partners, LP (“Averill Onshore”) and Averill Fund, Ltd. (“Averill Offshore”), which invest substantially all of their assets in Averill Master Fund, Ltd. (“Averill Master,” collectively with Averill Onshore and Averill Offshore, the “Averill Funds”);
• Averill Madison Partners, LP (“Madison Onshore”) and Averill Madison Fund, Ltd. (“Madison Offshore”), which invest substantially all of their assets in Averill Madison Master Fund, Ltd. (“Madison Master,” collectively with Madison Onshore and Madison Offshore, the “Madison Funds”); and
• Averill Opportunities Fund I LLC (“Averill Co-Invest Onshore”), which invest substantially all of its assets in Averill Opportunities Offshore Fund I LP (“Averill Co-Invest Mini- Master,” collectively with the Averill Co-Invest Onshore, the “Averill Co-Invest Funds,” and collectively with the Suvretta Fund, Averill Master and Madison Master, the “Master Funds”) alongside other Fund Investors who invest directly in the Averill Co- Invest Mini-Master. Suvretta GP, LLC (the “GP”) serves as the general partner to the Onshore Fund and a holder of certain allocation class shares in the Master Fund. Averill GP, LLC (“Averill GP”) serves as the general partner to Averill Onshore and a holder of certain allocation class shares in Averill Master. Averill Opportunities, LLC (“Averill Co-Invest GP”) serves as the general partner and managing member to Averill Co-Invest Funds, as applicable. Averill Madison GP, LLC (“Madison GP”) serves as the general partner to Madison Onshore and a holder of certain allocation class shares in Madison Master. The GP, Averill GP, Averill Co-Invest GP and Madison GP (collectively, the “General Partners”) are related entities of Suvretta. The Onshore Fund, Averill Onshore and Madison Onshore are Delaware limited partnerships and Averill Co-Invest Onshore is a Delaware limited liability company (altogether the “US Funds”). Interests in the US Funds are offered on a private placement basis, and in reliance on Section 3(c)(7) of the IC Act, to persons who are “accredited investors” as defined under Regulation D of the Securities Act and “qualified purchasers” as defined under the IC Act, subject to certain other conditions, which are set forth in each US Fund’s offering documents. The Offshore Fund, Averill Offshore and Madison Offshore are exempted companies incorporated under the laws of the Cayman Islands and Averill Co-Invest Mini-Master is a Cayman Islands exempted limited partnership (altogether the “Cayman Funds”). Shares or interests in the Cayman Funds are generally offered to persons on a private placement basis who (1) are not “U.S. persons,” as defined under Regulation S of the Securities Act, or such U.S. persons that may be offered interests in the US Funds, as described above, but are tax- exempt (or entities substantially comprised of tax-exempt U.S. persons), and (2) are subject to certain other conditions, which are set forth in each Cayman Fund’s offering documents. Each Master Fund, but for Averill Co-Invest Mini-Master, is an exempted company incorporated under the laws of the Cayman Islands. The purpose of each Master Fund is to achieve trading and administrative efficiencies. Each of the US Funds and the Offshore Funds (together, the “Feeder Funds”) invests all of its Investment Assets in its complex’s applicable Master Fund. “Investment Assets” means all assets other than cash, money market securities and other
liquid assets held for pending contribution to the Master Fund, distribution to investors, or payment of feeder-level expenses. Thus, an investment in the Feeder Funds is the functional and economic equivalent of an investment in a Master Fund. With regards to the Long-Short Funds, Suvretta seeks to achieve positive absolute returns, regardless of market conditions, on behalf of the Funds by investing primarily in equity securities (both long and short), with an emphasis on mid- to large-capitalization companies. Suvretta, through the Long-Short Funds, may invest in privately placed unregistered securities that do not have a readily ascertainable market value or other illiquid securities which may be valued but are not freely transferable (which are defined and designated as “Designated Investments”), subject to a 10% limitation as defined in the Onshore Fund’s and the Offshore Fund’s confidential private placement memorandums. With regards to the Averill and Madison Funds, Suvretta seeks to achieve risk-adjusted capital appreciation through a range of investment instruments in the healthcare industry, by adhering to its investment philosophy of generating returns through fundamental, bottom-up stock selection. With respect to the Averill Funds, Suvretta seeks to invest in companies in therapeutics-related companies, namely within the biotechnology and pharmaceuticals sectors, but may also invest in medical technology, healthcare services and other related sub- sectors. With respect to the Madison Funds, Suvretta seeks to invest primarily in companies in the healthcare sector, mostly defined as healthcare equipment and services, pharmaceuticals, biotechnology and life sciences, and other related sub-sectors. Suvretta, through each of the Averill Funds and Madison Funds, may invest in Designated Investments, subject to a 25% limitation as defined in Averill Onshore’s, Averill Offshore’s, Madison Onshore’s and Madison Offshore’s confidential private placement memorandums. With regards to the Averill Co-Invest Funds, Suvretta seeks capital appreciation by participating in financing of certain therapeutics-related portfolio companies alongside the Averill Funds by purchasing stock of such portfolio companies for the purpose of making direct and indirect investment(s) in securities issued by such portfolio companies, which investment(s) may be obtained in multiple transactions over time from any and all sources, including but not limited to, directly or indirectly from the portfolio companies or through secondary market transactions, including those involving or made through one or more special purpose vehicles. Suvretta manages the assets of the Funds in accordance with the investment strategy set forth in each Feeder Fund’s and each Averill Co-Invest Fund’s confidential private placement memorandum and, subject to certain investment restrictions, does not tailor its investment management services to the individual needs of Fund Investors. Suvretta also serves as sub-manager to a portion of an unaffiliated SICAV established under the laws of Luxembourg 0F 1 (“SICAV Sub-account”). Suvretta manages the SICAV Sub-account based on the investment advisory agreement between Suvretta and the SICAV’s investment manager and the investment guidelines in the SICAV’s prospectus and operating memorandum. Suvretta currently does not manage separate accounts for particular Clients (as defined herein). If Suvretta were to manage separate accounts, the accounts would be subject to investment objectives, guidelines, restrictions, fee arrangements and other terms that would be individually negotiated with each such Client pursuant to an investment advisory agreement. Separate accounts would generally involve significant account minimums. In addition to serving as the investment manager of the Averill Co-Invest Funds, Suvretta may in the future serve as investment manager to additional co-investment vehicles (“Co- Investment Vehicles”) that co-invest in certain investments along with one or more Funds. In this document, any reference to “Client” means the Funds, the Co-Investment Vehicles and their investors and any other advisory client of the Adviser. One or more affiliates of Suvretta previously sponsored, and may do so again in the future, special purpose acquisition vehicles (“Affiliated SPACs”) that were generally formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Suvretta does not participate in Wrap Fee Programs.